HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Monday, 24 September 2018

New commissioning policies for the following interventions…..

….based on reviews of clinical and economic evidence.  One of them concludes “NHS England has carefully reviewed the evidence for treating ‘x’ with ‘y’. We have concluded that there is not enough evidence of either clinical or cost effectiveness to consider making this treatment available for a selected group of patients.”

But which one is it…..?  You'll just have to read them......
  • Consultation on clinical commissioning policy: Metreleptin for congenital leptin deficiency
  • Clinical commissioning policies consultation for: Selective internal radiation therapy (SIRT) in the treatment of chemotherapy refractory and intolerant, unresectable metastatic colorectal cancer (all ages)Policy proposition on trientine for Wilson disease (all ages)
  • Consultation on a policy proposition for long term left ventricular assist device therapy for advanced heart failure (all ages)

Posted by at